Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events

•Co-medications must be carefully assessed at checkpoint inhibitors initiation.•Withdrawal of proton pump inhibitors and psychotropic drugs should be considered.•Antibiotic treatment should be limited to documented infections.•Baseline glucocorticoids should be reduced as much as possible.